The how's and why's of evidence based plasma therapy
Korean Journal of Hematology
; : 152-157, 2010.
Article
de En
| WPRIM
| ID: wpr-720399
Bibliothèque responsable:
WPRO
ABSTRACT
Although traditionally fresh frozen plasma (FFP) has been the product of choice for reversing a significant coagulopathy, the modern blood bank will have several different plasma preparations which should all be equally efficacious in reversing a significant coagulopathy or arresting coagulopathic bleeding. Emerging evidence suggests that for a stable patient, transfusing plasma for an INR< or =1.5 does not confer a hemostatic benefit while unnecessarily exposing the patient to the risks associated with plasma transfusion. This review will discuss the various plasma products that are available and present some of the current literature on the clinical uses of plasma.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Plasma sanguin
/
Banques de sang
/
Rapport international normalisé
/
Hémorragie
Limites du sujet:
Humans
langue:
En
Texte intégral:
Korean Journal of Hematology
Année:
2010
Type:
Article